The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 9 rounds in the feed, most often at Series B and in Biotech.
Seventure Partners, partenaire actif des sociétés innovantes dans les domaines des technologies digitales et des sciences de la vie.
Venture capitalParis, Franceseventure.frRounds from 2018-10-24 to ~ 2026-10-14
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Microbiotica A clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines | Series C Verified against 4 of 26 sources | $47.7M | ~ 2026-10-14 | [ PART ] |
ANote Music ANote Music sells music royalties, allowing individuals and businesses to buy, sell, and earn from music rights investments. | Funding round |
| $2.3M |
| 2026-09-29 |
| [ LEAD ] |
Wultra A provider of post-quantum authentication and digital identity solutions | Series A Developing, 11 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $7.6M | 2026-06-29 | [ LEAD ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $358.0M | 2025-10-15 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $139.8M | 2024-03-14 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $63.3M | 2022-05-03 | [ PART ] |
Microbiotica A clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines | Series B Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $65.9M | 2022-03-07 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $12.2M | 2020-07-21 | [ PART ] |
Microbiotica A clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines | Funding round Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $5.2M | 2018-10-24 | [ PART ] |